1. Home
  2. TPCS vs INTS Comparison

TPCS vs INTS Comparison

Compare TPCS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechPrecision Corporation

TPCS

TechPrecision Corporation

N/A

Current Price

$3.96

Market Cap

42.5M

Sector

Industrials

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.82

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPCS
INTS
Founded
1956
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.5M
13.2M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TPCS
INTS
Price
$3.96
$4.82
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
40.5K
28.8K
Earning Date
02-17-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
64.20
N/A
EPS
N/A
N/A
Revenue
$34,031,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.72
N/A
52 Week Low
$2.88
$0.19
52 Week High
$6.25
$8.06

Technical Indicators

Market Signals
Indicator
TPCS
INTS
Relative Strength Index (RSI) 52.69 33.18
Support Level $3.67 $0.29
Resistance Level $4.71 $8.06
Average True Range (ATR) 0.23 0.24
MACD -0.04 -0.03
Stochastic Oscillator 24.20 18.92

Price Performance

Historical Comparison
TPCS
INTS

About TPCS TechPrecision Corporation

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: